Matrix metalloproteinases: A review of their structure and role in systemic sclerosis

Journal of Clinical Immunology

Volumn 32, Issue 6, 2012, Pages 1409-1414

  Peng, Wen Jia ^a   Yan, Jun Wei ^a   Wan, Ya Nan ^a   Wang, Bing Xiang ^a   Tao, Jin Hui ^b   Yang, Guo Jun ^b   Pan, Hai Feng ^a   Wang, Jing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

fibrosis; inflammatory; inhibitor; Matrix metalloproteinase; systemic sclerosis

Indexed keywords

COLLAGENASE; COLLAGENASE 3; EPIDERMAL GROWTH FACTOR; GELATINASE; GELATINASE A; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 12; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 22; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 27; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; PLATELET DERIVED GROWTH FACTOR; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; COLLAGEN;

ARTICLE; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; FIBROSIS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION; CHROMOSOME MAP; ENZYMOLOGY; EXTRACELLULAR MATRIX; GENE LOCUS; GENETICS; HUMAN CHROMOSOME; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROMOTER REGION; REVIEW;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN; COLLAGEN; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETIC LOCI; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SCLERODERMA, SYSTEMIC; SUBSTRATE SPECIFICITY;

EID: 84878225353     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9735-7     Document Type: Article

References (59)

1. Gilliam AC. Scleroderma. Curr Dir Autoimmun. 2008;10:258-79.
2. Randone SB, Guiducci S, Cerinic MM. Systemic sclerosis and infections. Autoimmun Rev. 2008;8:36-40.
3. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vivo. J Clin Invest. 1974;54:880-9.
4. Uitto J, Bauer EA, Eisen AZ. Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts. J Clin Invest. 1979;64:921-30.
5. Peltonen J, Kahari L, Uitto J, Jimenez SA. Increased expression of type VI collagen genes in systemic sclerosis. Arthritis Rheum. 1990;33:1829-35.
6. Kuroda K, Shinkai H. Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metallopro-teinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res. 1997;289:567-72.
7. Fleischmajer R, Perlish JS, Krieg T, Trimpl R. Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol. 1981;76:400-3.
8. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets. 2009;10:1245-54.
9. Szarvas T, vom Dorp F, Ergün S, Rübben H, vom Dorp F, Ergün S. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol. 2011;8:241-54.
10. Amǎlinei C, Cǎruntu ID, Giuşcǎ SE, Bǎlan RA. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol. 2010;51:215-28.
11. Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-4.
12. Bode W, Maskos K. Structural studies on MMPs and TIMPs. Methods Mol Biol. 2001;151:45-77.
13. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-60.
14. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-39.
15. Gaggar A, Hector A, Bratcher PE, Mall MA, Griese M, Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J. 2011;38:721-7.
16. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res. 2002;90:251-62.
17. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211:19-26.
18. Fanjul-Fernández M, Folgueras AR, Cabrera S, López- Otín C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010;1803:3-19.
19. Hozumi A, Nishimura Y, Nishiuma T, Kotani Y, Yokoyama M. Induction of MMP-9 in normal human bronchial epithelial cells by TNF-alpha via NF-kappa B-mediated pathway. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1444-52.
20. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 2001;93:1375-84.
21. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res. 2001;29:4361-72.
22. Rouis M. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:541-8.
23. Van Wart HE, Birkeda-Hansenl H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA. 1990;87:5578-82.
24. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med. 2004;42:121-31.
25. Hulboy DL, Rudolph LA, Matrisian LM. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod. 1997;3:27-45.
26. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-33.
27. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci. 2008;45:291-338.
28. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59:812-23.
29. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leuk Biol. 2007;82:1375-81.
30. McGuire JK, Manicorne AM. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19:34-41.
31. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cell. Nature. 1997;385:729-33.
32. Ito A, Mukaiyama A, Itoh H, Nagase H, Thorgersen IB, Enghild JJ, et al. Degradation of interleukin 1 beta by matrix metalloproteinases. J Biol Chem. 1996;271:14657-60.
33. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol. 2010;37:11-25.
34. Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci. 2001;24 Suppl 1:S60-9.
35. Iimuro Y, Brenner DA. Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res. 2008;25:249-58.
36. Betsuyaku T, Fukuda Y, Parks WC, Shipley JM, Senior RM. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol. 2000;157:525-35.
37. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol. 2001;167:7017-26.
38. Pardo A, Ruiz V, Arreola JL, Ramirez R, Cisneros-Lira J, Gaxiola M, et al. Bleomycin-induced pulmonary fibrosis is attenuated in gamma-glutamyl transpeptidase-deficient mice. Am J Respir Crit Care Med. 2003;167:925-32.
39. Ruiz V, Ordóñez RM, Berumen J, Ramírez R, Uhal B, Becerril C, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2003;285:L1026-36.
40. Selman M, Ruiz V, Cabrera S, Segura L, Ramírez R, Barrios R, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol. 2000;279:L562-74.
41. Asano Y, Ihn H, Kubo M, Jinnin M, Mimura Y, Ashida R, et al. Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology (Oxford). 2006;45:303-7.
42. Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther. 2005;7:R71-9.
43. Andersen GN, Nilsson K, Pourazar J, Hackett TL, Kazzam E, Blomberg A, et al. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med. 2007;101:2199-206.
44. Moinzadeh P, Krieg T, Hellmich M, Brinckmann J, Neumann E, Müller-Ladner U, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol. 2011;20:770-3.
45. Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis. 2012;71:1064-72.
46. Kikuchi K, Kubo M, Hoashi T, Tamaki K. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol. 2002;27:301-5.
47. Marasini B, Casari S, Zeni S, Turri O, Biondi ML. Stromelysin promoter polymorphism is associated with systemic sclerosis. Rheumatology (Oxford). 2001;40:475-6.
48. Manetti M, Ibba-Manneschi L, Fatini C, Guiducci S, Cuomo G, Bonino C, et al. Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. J Rheumatol. 2010;37:1852-7.
49. Wipff J, Dieude P, Avouac J, Tiev K, Hachulla E, Cracowski JL, et al. Association of metalloproteinase gene polymorphisms with systemic sclerosis in the European Caucasian population. J Rheumatol. 2010;37:599-602.
50. Skarmoutsou E, D'Amico F, Marchini M, Stivala F, Malaponte G, Scorza R, et al. Analysis of matrix metalloproteinase-9 gene polymorphism -1562 C/T in patients suffering from systemic sclerosis with and without ulcers. Int J Mol Med. 2011;27:873-7.
51. Johnson RW, Reveille JD, McNearney T, Fischbach M, Friedman AW, Ahn C, et al. Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma). Genes Immun. 2001;2:273-5.
52. Joung CI, Na YI, Shin ES, Sung YK, Yoo DH, Jun JB. The single nucleotide polymorphisms of matrix metalloproteinase-1 in patients with systemic sclerosis. Rheumatol Int. 2008;28:1183-5.
53. Indelicato M, Chiarenza V, Libra M, Malaponte G, Bevelacqua V, Marchini M, et al. Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. J Clin Lab Anal. 2006;20:173-6.
54. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol. 2003;120:542-7.
55. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol. 2004;138:357-63.
56. Serratì S, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol. 2006;210:240-8.
57. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 2004;50:3275-85.
58. Margheri F, Manetti M, Serratì S, Nosi D, Pucci M, Matucci-Cerinic M, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006;54:3926-38.
59. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009;11:111-9. Natural Science Research